IRIS Accounts Production v25.2.0.378 11683257 director 1.12.23 30.11.24 30.11.24 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh116832572023-11-30116832572024-11-30116832572023-12-012024-11-30116832572022-11-30116832572022-12-012023-11-30116832572023-11-3011683257ns15:EnglandWales2023-12-012024-11-3011683257ns14:PoundSterling2023-12-012024-11-3011683257ns10:Director12023-12-012024-11-3011683257ns10:PrivateLimitedCompanyLtd2023-12-012024-11-3011683257ns10:SmallEntities2023-12-012024-11-3011683257ns10:AuditExempt-NoAccountantsReport2023-12-012024-11-3011683257ns10:SmallCompaniesRegimeForDirectorsReport2023-12-012024-11-3011683257ns10:SmallCompaniesRegimeForAccounts2023-12-012024-11-3011683257ns10:FullAccounts2023-12-012024-11-301168325712023-12-012024-11-3011683257ns10:OrdinaryShareClass12023-12-012024-11-3011683257ns10:RegisteredOffice2023-12-012024-11-3011683257ns5:CurrentFinancialInstruments2024-11-3011683257ns5:CurrentFinancialInstruments2023-11-3011683257ns5:Non-currentFinancialInstruments2024-11-3011683257ns5:Non-currentFinancialInstruments2023-11-3011683257ns5:ShareCapital2024-11-3011683257ns5:ShareCapital2023-11-3011683257ns5:RetainedEarningsAccumulatedLosses2024-11-3011683257ns5:RetainedEarningsAccumulatedLosses2023-11-3011683257ns5:NetGoodwill2023-12-012024-11-3011683257ns5:IntangibleAssetsOtherThanGoodwill2023-12-012024-11-3011683257ns5:FurnitureFittings2023-12-012024-11-3011683257ns5:MotorVehicles2023-12-012024-11-3011683257ns5:ComputerEquipment2023-12-012024-11-3011683257ns5:NetGoodwill2023-11-3011683257ns5:NetGoodwill2024-11-3011683257ns5:NetGoodwill2023-11-3011683257ns5:LeaseholdImprovements2023-11-3011683257ns5:PlantMachinery2023-11-3011683257ns5:FurnitureFittings2023-11-3011683257ns5:LeaseholdImprovements2023-12-012024-11-3011683257ns5:PlantMachinery2023-12-012024-11-3011683257ns5:LeaseholdImprovements2024-11-3011683257ns5:PlantMachinery2024-11-3011683257ns5:FurnitureFittings2024-11-3011683257ns5:LeaseholdImprovements2023-11-3011683257ns5:PlantMachinery2023-11-3011683257ns5:FurnitureFittings2023-11-3011683257ns5:MotorVehicles2023-11-3011683257ns5:ComputerEquipment2023-11-3011683257ns5:MotorVehicles2024-11-3011683257ns5:ComputerEquipment2024-11-3011683257ns5:MotorVehicles2023-11-3011683257ns5:ComputerEquipment2023-11-3011683257ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3011683257ns5:WithinOneYearns5:CurrentFinancialInstruments2023-11-3011683257ns5:DeferredTaxation2023-11-3011683257ns5:DeferredTaxation2023-12-012024-11-3011683257ns5:DeferredTaxation2024-11-3011683257ns10:OrdinaryShareClass12024-11-3011683257ns5:RetainedEarningsAccumulatedLosses2023-11-3011683257ns5:RetainedEarningsAccumulatedLosses2023-12-012024-11-30
REGISTERED NUMBER: 11683257 (England and Wales)












Unaudited Financial Statements

for the Year Ended 30 November 2024

for

Redcliffe Hill Pharma Ltd

Redcliffe Hill Pharma Ltd (Registered number: 11683257)






Contents of the Financial Statements
for the Year Ended 30 November 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Redcliffe Hill Pharma Ltd

Company Information
for the Year Ended 30 November 2024







DIRECTOR: Mr M A Akbar





REGISTERED OFFICE: 8 Waring House
Redcliffe Hill
Bristol
BS1 6TB





REGISTERED NUMBER: 11683257 (England and Wales)





ACCOUNTANTS: Wormald & Partners
Chartered Accountants (ICAEW)
Brunel House
11 The Promenade
Clifton Down
Bristol
BS8 3NG

Redcliffe Hill Pharma Ltd (Registered number: 11683257)

Balance Sheet
30 November 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 1,383,648 1,788,879
Tangible assets 5 269,712 65,790
1,653,360 1,854,669

CURRENT ASSETS
Stocks 6 242,075 117,602
Debtors 7 940,769 946,165
Cash at bank and in hand 249,139 306,658
1,431,983 1,370,425
CREDITORS
Amounts falling due within one year 8 1,378,311 1,275,923
NET CURRENT ASSETS 53,672 94,502
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,707,032

1,949,171

CREDITORS
Amounts falling due after more than one
year

9

(1,571,336

)

(1,587,657

)

PROVISIONS FOR LIABILITIES 11 (62,617 ) (10,580 )
NET ASSETS 73,079 350,934

CAPITAL AND RESERVES
Called up share capital 12 5,000 5,000
Retained earnings 13 68,079 345,934
SHAREHOLDERS' FUNDS 73,079 350,934

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 23 July 2025 and were signed by:




Mr M A Akbar - Director


Redcliffe Hill Pharma Ltd (Registered number: 11683257)

Notes to the Financial Statements
for the Year Ended 30 November 2024

1. STATUTORY INFORMATION

Redcliffe Hill Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2019, is being amortised evenly over its estimated useful life of five years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 15% on reducing balance basis
Motor vehicles - 25% on reducing balance basis
Computer equipment - 33.33% on reducing balance basis

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Redcliffe Hill Pharma Ltd (Registered number: 11683257)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 45 (2023 - 31 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 December 2023
and 30 November 2024 2,164,902
AMORTISATION
At 1 December 2023 376,023
Amortisation for year 405,231
At 30 November 2024 781,254
NET BOOK VALUE
At 30 November 2024 1,383,648
At 30 November 2023 1,788,879

5. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and
property machinery fittings
£    £    £   
COST
At 1 December 2023 - - 13,834
Additions 42,000 170,000 11,259
At 30 November 2024 42,000 170,000 25,093
DEPRECIATION
At 1 December 2023 - - 2,877
Charge for year 3,500 - 2,402
At 30 November 2024 3,500 - 5,279
NET BOOK VALUE
At 30 November 2024 38,500 170,000 19,814
At 30 November 2023 - - 10,957

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 December 2023 81,698 23,977 119,509
Additions - 2,180 225,439
At 30 November 2024 81,698 26,157 344,948
DEPRECIATION
At 1 December 2023 42,540 8,302 53,719
Charge for year 9,790 5,825 21,517
At 30 November 2024 52,330 14,127 75,236
NET BOOK VALUE
At 30 November 2024 29,368 12,030 269,712
At 30 November 2023 39,158 15,675 65,790

Redcliffe Hill Pharma Ltd (Registered number: 11683257)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

6. STOCKS
2024 2023
£    £   
Stocks 242,075 117,602

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 558,178 654,161
Other debtors 202,897 137,990
Pharmacy purchase costs 14,191 -
Akbar Management Loan 154,014 154,014
Prepayments 11,489 -
940,769 946,165

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts (see note 10) 173,753 267,405
Trade creditors 1,033,799 794,462
Tax 110,877 62,960
Social security and other taxes 29,315 55,406
Pension Control 3,151 2,800
Other creditors - 20,000
Directors' loan accounts 12,892 54,026
Accrued expenses 14,524 18,864
1,378,311 1,275,923

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2023
£    £   
Bank loans (see note 10) 1,571,336 1,587,657

Amounts falling due in more than five years:

Repayable otherwise than by instalments
Bounceback Loan 15,000 25,000

Repayable by instalments
Bank loans more 5 yr by instal 1,556,336 1,562,657

10. LOANS

An analysis of the maturity of loans is given below:

2024 2023
£    £   
Amounts falling due within one year or on demand:
Bank overdrafts 2,921 -
Bank loans 170,832 267,405
173,753 267,405

Amounts falling due in more than five years:
Repayable otherwise than by instalments
Bounceback Loan 15,000 25,000

Redcliffe Hill Pharma Ltd (Registered number: 11683257)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

10. LOANS - continued
2024 2023
£    £   
Repayable by instalments
Bank loans more 5 yr by instal 1,556,336 1,562,657

11. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax 62,617 10,580

Deferred
tax
£   
Balance at 1 December 2023 10,580
Provided during year 52,037
Balance at 30 November 2024 62,617

12. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
5,000 Ordinary 1 5,000 5,000

13. RESERVES
Retained
earnings
£   

At 1 December 2023 345,934
Deficit for the year (277,855 )
At 30 November 2024 68,079